Field note · July 2026

The Fifteen Days Nobody Staffs For

An investigator closes a laptop, hands over a Form 483, and walks out of the building. What happens over the next fifteen business days decides whether that document stays a piece of paper or turns into a warning letter, then an import alert, then a consent decree with a court-supervised expert living in the plant.

Fifteen business days is the response window FDA recommends. The agency is careful to call it a recommendation. Everyone who has actually been through it treats it as a hard deadline, because a late or thin response is itself evidence of a quality system that cannot correct itself, and that is a far worse finding than whatever was on the original form.

The trap is structural. The response demands precisely the capability the 483 just documented as missing. A firm cited for inadequate root-cause investigation now has three weeks to produce a root-cause investigation good enough to satisfy the people who cited it. Same team, same procedures, same blind spot that generated the observation in the first place.

The findings land on the exact day a company is least equipped to answer them. That is not a failure of effort. It is the shape of the problem.

The ladder has price tags on every rung. A warning letter converts to an import alert that freezes product at the border under Detention Without Physical Examination — the practical removal timeline is twelve to twenty-four months, during which shipments are refused at entry and must be destroyed or exported within ninety days. For a mid-size manufacturer with product in foreign distribution, an import alert is not a compliance event. It is a liquidity event. A warning letter that converts to a consent decree is a different category of problem entirely: remediation runs $500K to $5M for smaller firms, and that number is structurally uncapped above it. Genzyme paid $175M in penalties before remediation costs. Ranbaxy and its acquirer paid $500M to settle associated litigation. Only 11.7% of warning letters in FDA’s published record have ever received close-out letters, and those took an average of 486 days to close. The ladder, once climbed, is slow to descend.

So they reach outside. Somewhere there is a former investigator, or a quality consultant who has written forty of these, who knows what the district office reads first and which three words in a CAPA plan trigger a follow-up inspection. That person exists. Senior regulatory consultants with FDA interaction experience bill at $325–$500 per hour, with former FDA employees at the top of that range. A full 483 response engagement — scoping, root cause analysis, CAPA drafting, response document — typically runs $50,000 to $200,000 depending on the number of observations and the depth of the quality system failure underneath them. The cost is not the problem. The problem is access. There is no directory of qualified 483 response specialists, no clearinghouse that maps consultant expertise to observation type or district office, no relationship already in place. Nobody builds a relationship with a remediation lead before the inspection. The firm that receives a 483 on a Tuesday is making cold calls by Thursday, triaging résumés by Friday, and hoping someone credible is available to start the following week — inside a fifteen-business-day window that is already running.

Every rung of that ladder is public and dated. Warning letter issuance rose from 2.98 per 100 inspections in 2019 to 4.27 by 2023 — a 43% increase in enforcement rate even as inspection volume has not recovered to pre-pandemic levels. Between July and December 2025 alone, FDA issued 327 warning letters, a 73% increase over the same period in 2024. The agency is not slowing down. You can watch a firm travel from observation to warning letter to import alert entirely in the open record. The one thing the record never shows is whether anyone reached them in the fifteen days that mattered most. That gap is the introduction.

— Krishanu routes between firms with an open FDA finding and the operators who close them.

Sources: FDLI Warning Letter Statistical Update (Oct 2025) · Reed Smith FDA Inspections in 2025 (Dec 2025) · Springer / Journal of Pharmaceutical Innovation (2024) · Redica Systems Consent Decree Case Studies · Cloudtheapp FDA Consent Decree Analysis (2026) · MedEnvoy Regulatory Consulting Rates (2026) · NSF FDA 483 Response Guidance · FDA public enforcement database